# TROP2

Source: https://onco.cc/targets/trop2/  
OnCo record `trop2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TROP2 is a surface glycoprotein present at high levels on most epithelial cancers (breast, lung, urothelial, gastric, pancreatic) and at low levels on normal tissue. It does not drive the cancer; it is a delivery address, used by the approved ADCs sacituzumab govitecan and datopotamab deruxtecan and by sacituzumab tirumotecan, with a TROP2 PET tracer in development to pick patients.

## Summary

Trophoblast cell-surface antigen 2 is a transmembrane glycoprotein overexpressed in most epithelial cancers (breast, lung, urothelial, gastric, pancreatic) with low normal-tissue expression. It is not an oncogenic driver; it is a delivery address. Three TROP2 ADCs are approved or in registration (sacituzumab govitecan, datopotamab deruxtecan, sacituzumab tirumotecan) and a TROP2 PET tracer is in development to select patients.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Tags: adc-target; pet-target
- Symbol: TACSTD2
- Class: surface-antigen
- Biology: Regulates calcium signalling and cell adhesion; overexpression correlates with shorter survival. Expression is heterogeneous within tumours, which limits the value of IHC selection. Internalises on antibody binding and traffics to lysosomes, which is what makes it a good ADC target.
- Where found: Triple-negative breast cancer (~80-90% express); HR+ breast cancer; NSCLC; Urothelial carcinoma; Gastric, pancreatic, endometrial cancers; Triple-negative breast cancer: protein expression (h-score) and amplification 2-4%

## Notes

- Triple-negative breast cancer: sacituzumab govitecan benefit was seen at high and medium Trop-2 H-score in ASCENT with a low group too small to judge (Bardia 2021); no label requires the test. TACSTD2 amplification is rare, 2.5 to 4.4% (cBioPortal).

## Sources

- UniProt P09758: TACSTD2 (TROP2): https://www.uniprot.org/uniprotkb/P09758/entry

## Connected records

- biomarkers: [TROP2 expression](https://onco.cc/biomarkers/trop2-expression/)
- cancers: [Adenocarcinoma of the lung](https://onco.cc/cancers/lung-adenocarcinoma/), [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Cervical cancer](https://onco.cc/cancers/cervical/), [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [PD-L1-high non-small-cell lung cancer without a driver mutation](https://onco.cc/cancers/pdl1-high-nsclc/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [AK146D1](https://onco.cc/drugs/ak146d1/), [BIO-106](https://onco.cc/drugs/bio-106/), [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [EB-NK-301](https://onco.cc/drugs/eb-nk-301/), [LCB84](https://onco.cc/drugs/lcb84/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- trials: [ASCENT](https://onco.cc/trials/ascent/), [Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors](https://onco.cc/trials/nct07299747/), [DIAMOND](https://onco.cc/trials/diamond/), [TROPiCS-02](https://onco.cc/trials/tropics-02/), [TROPION-Lung05](https://onco.cc/trials/tropion-lung05/)
- key papers: [ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer](https://onco.cc/key-papers/paper-ascent-nejm-2021/), [Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer](https://onco.cc/key-papers/paper-bardia-ascent-trop2-biomarker-ann-oncol-2021/), [Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update](https://onco.cc/key-papers/paper-asco-biomarkers-metastatic-breast-cancer-guideline-jco-2022/), [Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial](https://onco.cc/key-papers/paper-tropion-breast02-ann-oncol-2026/), [TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival](https://onco.cc/key-papers/paper-tropion-breast01-jco-2024/)
- terms: [Antigen](https://onco.cc/terms/antigen/), [HER2-low eligibility for trastuzumab deruxtecan, and TROP2 ADCs without a test (triple-negative disease)](https://onco.cc/terms/her2-low-and-trop2-adc-eligibility-tnbc/), [Overexpression](https://onco.cc/terms/overexpression/)
- roadmaps: [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/), [TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET](https://onco.cc/roadmaps/trop2-adc-roadmap/)
- ideas: [A randomised trial of antibody-drug conjugate sequence in metastatic triple-negative breast cancer](https://onco.cc/ideas/idea-tnbc-adc-sequencing-trial/), [Alpha radioligands after ADC failure](https://onco.cc/ideas/idea-alpha-after-adc/), [Bispecific antibodies that engage macrophages instead of T cells](https://onco.cc/ideas/idea-bio2-myeloid-engager-bispecific/), [Dual-payload ADCs in first line to prevent resistance](https://onco.cc/ideas/idea-dual-payload-first/), [Re-map the tumour's surface proteins before choosing the next antibody drug](https://onco.cc/ideas/idea-bio1-antigen-mapping-at-progression/), [Shorter exclusivity for later-in-class drugs without added benefit](https://onco.cc/ideas/idea-fund-benefit-indexed-exclusivity/), [TROP2 PET to choose and sequence TROP2 ADCs](https://onco.cc/ideas/idea-trop2-pet-selection/), [Use the brain's own transport door to carry antibody drugs across](https://onco.cc/ideas/idea-bio2-transferrin-shuttle-adc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Bispecific ADC](https://onco.cc/technologies/bispecific-adc/), [Immuno-PET](https://onco.cc/technologies/immuno-pet/), [TROP2 PET](https://onco.cc/technologies/trop2-pet/)
- companies: [Avenzo Therapeutics](https://onco.cc/companies/avenzo/), [Pathos AI](https://onco.cc/companies/pathos-ai/)
- institutions: [Fudan University Shanghai Cancer Center](https://onco.cc/institutions/fuscc/)
- pathways: [DNA replication & origin licensing](https://onco.cc/pathways/dna-replication-licensing/), [Drug efflux pumps (ABC transporters)](https://onco.cc/pathways/drug-efflux-pumps/), [Epithelial-mesenchymal transition & drug efflux](https://onco.cc/pathways/emt/)
- pairings: [TROP2 PET → TROP2 ADC selection](https://onco.cc/pairings/trop2-pet-to-adc/)
- people: [Aditya Bardia](https://onco.cc/people/aditya-bardia/), [Binghe Xu](https://onco.cc/people/xu-binghe/), [Hope S. Rugo](https://onco.cc/people/hope-rugo/), [Joohyuk Sohn](https://onco.cc/people/sohn-joohyuk/), [Sara M. Tolaney](https://onco.cc/people/sara-tolaney/), [Shaoli Song](https://onco.cc/people/song-shaoli/)
- bottlenecks: [Biomarkers are not validated or standardised](https://onco.cc/bottlenecks/b-biomarker-validation/), [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/)

---
JSON: https://onco.cc/api/v1/entities/trop2.json